Elixir Pharmaceuticals, Inc.

We are a pharmaceutical company focused on the discovery, development, and commercialization of novel pharmaceuticals for the treatment of metabolic diseases such as diabetes and obesity. We mine the pathways involved in the regulation of aging discovered by our founders to identify novel mechanisms leading to the development of compounds to treat metabolic disease, compounds that may ultimately be used to treat a host of age-related diseases. Metabolic diseases, including our primary targets of type 2 diabetes and obesity, constitute important global pharmaceutical markets in terms of size, growth and unmet medical need. Obesity rates are on the rise not only in the U.S. but also around the world, and are contributing to a worldwide epidemic of type 2 diabetes. Despite the high prevalence, expected growth, and injurious health consequences of these diseases, there are relatively few satisfactory therapeutic options available. We have several programs in various phases of development to address unmet medical needs within these large commercial markets. For example, our phase III Glinsuna (mitiglinide) and Metgluna (mitiglinide plus metformin) programs represent near-term commercial opportunities in the U.S. for the treatment of type 2 diabetes. Our ghrelin antagonists represent a potential novel approach to treating metabolic diseases, and we have confirmed the favorable effects of treatment with our compounds across a range of metabolic parameters in animal models. ...